- CaruMonaM
-
- $1.00 / 1g
-
2021-07-20
- CAS:87638-04-8
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50tons
- CARUMONAM USP/EP/BP
-
- $1.10 / 1g
-
2021-06-22
- CAS:87638-04-8
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
- CARUMONAM
-
- $1.00 / 1g
-
2019-12-26
- CAS:87638-04-8
- Min. Order: 1g
- Purity: ≥98%
- Supply Ability: g/kg/Ton
|
| | CARUMONAM Basic information |
| Product Name: | CARUMONAM | | Synonyms: | CARUMONAM;Acetic acid, [[(Z)-[2-[[(2S,3S)-2-[[(aminocarbonyl)oxy]methyl]-4-oxo-1-sulfo-3-azetidinyl]amino]-1-(2-amino-4-thiazolyl)-2-oxoethylidene]amino]oxy]-;Acetic acid, [[[2-[[2-[[(aminocarbonyl)oxy]methyl]-4-oxo-1-sulfo-3-azetidinyl]amino]-1-(2-amino-4-thiazolyl)-2-oxoethylidene]amino]oxy]-, [2S-[2α,3α(Z)]]-;AMA 1080;Antibiotic Ro 17-2301;Ro 17-2301;(2S)-2α-(Carbamoyloxymethyl)-3α-[[(Z)-(2-amino-4-thiazolyl)[(carboxymethoxy)imino]acetyl]amino]-4-oxoazetidine-1-sulfonic acid;[[[(Z)-2-[[(2S)-2α-[[(Aminocarbonyl)oxy]methyl]-4-oxo-1-sulfoazetidin-3α-yl]amino]-1-(2-aminothiazol-4-yl)-2-oxoethylidene]amino]oxy]acetic acid | | CAS: | 87638-04-8 | | MF: | C12H14N6O10S2 | | MW: | 466.4 | | EINECS: | | | Product Categories: | | | Mol File: | 87638-04-8.mol |  |
| | CARUMONAM Chemical Properties |
| alpha | D26 -45° (c = 1 in DMSO) | | density | 2.13±0.1 g/cm3(Predicted) | | pka | -0.43±0.60(Predicted) |
| | CARUMONAM Usage And Synthesis |
| Description | Canunonam is an injectable antibiotic, the second monobactam ever developed (the first
being Squibb’s aztreonam). It is highly active against Gram negative bacteria, particularly
pseudomom, and is reportedly effective in the treatment of pneumonia, cystitis,
peritonitis and secondary infections. | | Originator | Takeda (Japan) | | Definition | ChEBI: An N-sulfonated monobactam antibiotic. | | Brand name | Amasulin | | Antimicrobial activity | A synthetic monobactam with activity against common
pathogenic organisms similar to that of aztreonam. It is resistant
to hydrolysis by the common plasmid and chromosomal
β-lactamases, but it can be hydrolyzed by ESBLs.
It is administered intravenously, achieving a concentration
of c. 78 mg/L after a 20-min infusion of 1 g. The plasma halflife
is 1.7 h and the plasma protein binding 18–28%.
Carumonam is almost entirely eliminated in the glomerular
filtrate, probenecid having no effect on excretion; 96%
of labeled compound is found in the urine, with 3% in the
feces. Between 68% and 91% of the dose appears in the urine
within 24 h.
Side effects and clinical use are similar to those of
aztreonam. |
| | CARUMONAM Preparation Products And Raw materials |
|